Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GMA-301 by Gmax Biopharm for Pulmonary Arterial Hypertension: Likelihood of Approval
GMA-301 is under clinical development by Gmax Biopharm and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData,...